Medindia LOGIN REGISTER
Medindia
Advertisement

Medimetriks Pharmaceuticals, Inc. Welcomes Wolfgang Kunze to Its Board of Directors

Monday, September 22, 2008 General News
Advertisement
FAIRFIELD, N.J., Sept. 22 Medimetriks Pharmaceuticals,Inc. announced today that Wolfgang Kunze has been added to its Board ofDirectors. Mr. Kunze joins Daniel Glassman on the Board of the Companyfounded this spring by Mr. Glassman and other senior management staff of theformer Bradley Pharmaceuticals, Inc. Medimetriks develops, licenses andcommercializes innovative prescription products primarily for the Dermatologyand Podiatry marketplaces.
Advertisement

"I am pleased to join this dynamic organization," said Mr. Kunze. "Thetrack record of the Medimetriks Management Team and its committed staff speaksfor itself. I am confident that the Company will be successful in achievingits Corporate Mission of enhancing patient quality-of-life with innovativeprescription Dermatology and Podiatry therapies. I look forward tocontributing to the Company's success."
Advertisement

Mr. Kunze, who will serve as the Audit Committee Chairman, brings morethan 30 years of experience in the pharmaceutical industry to Medimetriks. Heis the former Executive Vice President, Finance, and Chief Financial Officerof Bayer HealthCare Pharmaceuticals Inc. (BHCP), the successor of Berlex Inc.headquartered in Montville, NJ. He retired from BHCP in March of 2008. From1993 to 2006, Mr. Kunze served as Executive Vice President, Finance, and ChiefFinancial Officer of Berlex Inc. He spent the majority of his career withSchering AG, Germany and its affiliates in the United States. In 1979, he wasappointed Chief Financial Officer of Schering Berlin Inc., the U.S. holdingcompany of Schering AG, and moved to the United States. Mr. Kunze wasinvolved in all major acquisitions and divestitures during the build-up andrestructuring of Schering AG's U.S. business, and served on the Board ofDirectors of several subsidiaries of Schering Berlin Inc., including BerlexInc. and Medrad, Inc., a major medical device company headquartered inPittsburgh, PA.

"We are delighted to welcome such an accomplished executive as Mr. Kunzeto our Board," stated Daniel Glassman, Chairman of the Board. "Mr. Kunze'sexperience will be important to Medimetriks as we pursue our core strategy ofacquiring, developing and marketing patent-protected, brand-name therapies tothe Dermatology and Podiatry specialties. We currently are evaluating anumber of licensing and acquisition opportunities parallel to our own productdevelopment efforts. Mr. Kunze's insight will be important as we deliver onour aggressive plans of launching new products and building a robust portfolioof innovative brands."

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals, Inc., which commenced operations May 1, 2008,develops, licenses and commercializes prescription skincare products for theDermatology and Podiatry marketplaces. The Company's mission is to enhancepatient quality-of-life by providing innovative therapies that advance patientcare.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402.Please visit the Medimetriks website at www.medimetriks.com, call(973) 882-7512 or fax (973) 882-7502.

SOURCE Medimetriks Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close